The purpose of this study is to evaluate the pharmacokinetics (PK) of xanomeline following administration of KarXT in CYP2D6 normal/extensive, intermediate, poor, and ultrarapid metabolizers.
Participant must be healthy male and female (INOCBP) participants as determined by no clinically significant deviation from normal in medical history, physical examination, 12-lead electrocardiogram (ECG), vital signs (VS), and clinical laboratory determinations.
Participant must be a normal/extensive, intermediate, poor, or ultrarapid CYP2D6 metabolizer.
Participant must have body mass index (BMI) of 18.0 to 32.0 kg/m2, inclusive.
Participants must not have evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, 12-lead ECG, or clinical laboratory determinations beyond what is consistent with the target population reference ranges.
Other protocol-defined Inclusion/Exclusion criteria apply.